Skip to Main Content

Paper Details

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Eur J Cancer
8
2023
BRCA1, BRCA2, BRCAwt, HR genes, HRD, PARP, TP53, Tumours, coding exons, homologous recombination deficient, olaparib, ovarian cancer, patients, tumours
Author NameAffiliation
Isabelle Ray-CoquardCentre Leon Berard University Claude Bernard
Diether LambrechtsKU Leuven VIB Center for Cancer Biology
  • 1 - 2

Datasets

Release 1.2